{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:13:44Z","timestamp":1790187224578,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,2]],"date-time":"2027-01-02T00:00:00Z","timestamp":1798848000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970622"],"award-info":[{"award-number":["81970622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK133912"],"award-info":[{"award-number":["R01DK133912"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK131525"],"award-info":[{"award-number":["R01DK131525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017618","name":"NIDDK Division of Diabetes Endocrinology and Metabolic Diseases","doi-asserted-by":"publisher","award":["R01DK129467"],"award-info":[{"award-number":["R01DK129467"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017618","name":"NIDDK Division of Diabetes Endocrinology and Metabolic Diseases","doi-asserted-by":"publisher","award":["R01DK141510"],"award-info":[{"award-number":["R01DK141510"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.kint.2025.09.023","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:48:50Z","timestamp":1761299330000},"page":"81-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New potential therapeutic targets of metabolic disorder\u2013associated kidney disease and diabetic kidney disease"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-9140","authenticated-orcid":false,"given":"Xuezhu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Cijiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-1765","authenticated-orcid":false,"given":"Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.09.023_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107260","article-title":"SGLT1\/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes","volume":"26","author":"Herat","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.kint.2025.09.023_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1681\/ASN.0000000000000498","article-title":"Targeting KLF2 as a novel therapy for glomerular endothelial cell injury in diabetic kidney disease","volume":"36","author":"Min","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib3","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/ijms18112383","article-title":"KLF2 in regulation of NF-kappaB-mediated immune cell function and inflammation","volume":"18","author":"Jha","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2025.09.023_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.09.023_bib56","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.0000000000000212","article-title":"Podocyte injury in diabetic kidney disease in mouse models involves TRPC6-mediated calpain activation impairing autophagy","volume":"34","author":"Salemkour","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165207","article-title":"TYRO3 agonist as therapy for glomerular disease","volume":"8","author":"Zhong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2025.09.023_bib9","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1172\/JCI125316","article-title":"ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes","volume":"129","author":"Ducasa","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.09.023_bib10","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1038\/s41467-021-24890-3","article-title":"Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease","volume":"12","author":"Wright","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib11","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Merscher-Gomez","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2025.09.023_bib12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-beta-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib13","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/s41467-019-10584-4","article-title":"SMPDL3b modulates insulin receptor signaling in diabetic kidney disease","volume":"10","author":"Mitrofanova","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154748","article-title":"Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy","volume":"118","author":"Wu","year":"2021","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.kint.2025.09.023_bib15","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.18632\/aging.204897","article-title":"Inhibiting NLRP3 signaling in aging podocytes improves their life- and health-span","volume":"15","author":"Kaverina","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.kint.2025.09.023_bib16","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.2337\/db09-1631","article-title":"Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy","volume":"59","author":"Li","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2025.09.023_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7150\/ijbs.87820","article-title":"Treatment for type 2 diabetes and diabetic nephropathy by targeting Smad3 signaling","volume":"20","author":"He","year":"2024","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.kint.2025.09.023_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.2015.121","article-title":"Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance","volume":"88","author":"Sun","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib19","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1681\/ASN.0000000000000327","article-title":"Small molecule allosteric inhibitor of HIPK2 as a novel therapy against kidney fibrosis","volume":"35","author":"Lee","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib20","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1681\/ASN.2016080841","article-title":"A novel inhibitor of homeodomain interacting protein kinase 2 mitigates kidney fibrosis through inhibition of the TGF-beta1\/Smad3 pathway","volume":"28","author":"Liu","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.0000000000000418","article-title":"Effect of avenciguat on albuminuria in patients with CKD: two randomized placebo-controlled trials","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib22","article-title":"Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution","volume":"4","author":"Balzer","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.kint.2025.09.023_bib23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","article-title":"The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease","volume":"97","author":"Hasegawa","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib25","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.2215\/CJN.02180311","article-title":"Metabolic syndrome and kidney disease: a systematic review and meta-analysis","volume":"6","author":"Thomas","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.ajkd.2018.02.362","article-title":"Obesity, metabolic abnormality, and progression of CKD","volume":"72","author":"Yun","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.023_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40200-023-01348-5","article-title":"Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies","volume":"23","author":"Valizadeh","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.kint.2025.09.023_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"99","key":"10.1016\/j.kint.2025.09.023_bib29","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2025.09.023_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2025.09.023_bib31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2024.05.006","article-title":"Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging","volume":"106","author":"Wada","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2025.09.023_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/dom.16094","article-title":"Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients","volume":"27","author":"Cersosimo","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2025.09.023_bib35","doi-asserted-by":"crossref","first-page":"F207","DOI":"10.1152\/ajprenal.00120.2019","article-title":"Knockout of Na(+)-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration","volume":"317","author":"Song","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2025.09.023_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.kint.2021.10.037","article-title":"Role of the macula densa sodium glucose cotransporter type 1-neuronal nitric oxide synthase-tubuloglomerular feedback pathway in diabetic hyperfiltration","volume":"101","author":"Zhang","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1871529X14666140401110841","article-title":"Renal endothelial dysfunction in diabetic nephropathy","volume":"14","author":"Cheng","year":"2014","journal-title":"Cardiovasc Hematological Disord Drug Targets"},{"key":"10.1016\/j.kint.2025.09.023_bib38","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2337\/diabetes.51.10.3090","article-title":"Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody","volume":"51","author":"Flyvbjerg","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2025.09.023_bib39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","article-title":"Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes","volume":"12","author":"Vriese","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib40","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.023_bib41","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.023_bib42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.09.023_bib43","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1523-1755.2005.00575.x","article-title":"VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells","volume":"68","author":"Feliers","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ki.2014.286","article-title":"Reduced Kruppel-like factor 2 expression may aggravate the endothelial injury of diabetic nephropathy","volume":"87","author":"Zhong","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111699","article-title":"Endothelial Kruppel-like factor 2\/4: regulation and function in cardiovascular diseases","volume":"130","author":"Gao","year":"2025","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2025.09.023_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nm.3843","article-title":"Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models","volume":"21","author":"Schiffer","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.09.023_bib6","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/s41467-022-30101-4","article-title":"Simultaneous stabilization of actin cytoskeleton in multiple nephron-specific cells protects the kidney from diverse injury","volume":"13","author":"Mukherjee","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib46","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1681\/ASN.0000000000000415","article-title":"Treatment of podocytopathies: risky business and our personal journey","volume":"35","author":"Sever","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib47","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.023_bib49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.023_bib50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.09.023_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.746151","article-title":"Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites","volume":"12","author":"Russo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.09.023_bib52","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib53","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.09.023_bib54","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.09.023_bib55","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1681\/ASN.0000000000000444","article-title":"Selonsertib in patients with diabetic kidney disease: a phase 2b randomized active run-in clinical trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2011.05.004","article-title":"NLRP3 inflammasomes link inflammation and metabolic disease","volume":"32","author":"De Nardo","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1016\/j.kint.2025.09.023_bib58","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.kint.2022.06.010","article-title":"Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease","volume":"102","author":"Shahzad","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1230050","article-title":"No NLRP3 inflammasome activity in kidney epithelial cells, not even when the NLRP3-A350V Muckle-Wells variant is expressed in podocytes of diabetic mice","volume":"14","author":"Kunte","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.09.023_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"10.1016\/j.kint.2025.09.023_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.ackd.2016.11.002","article-title":"Treatment of renal fibrosis\u2014turning challenges into opportunities","volume":"24","author":"Klinkhammer","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2025.09.023_bib62","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.7150\/ijbs.101548","article-title":"Modulation of TGF-\u03b2 signaling new approaches toward kidney disease and fibrosis therapy","volume":"21","author":"Hong","year":"2025","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.kint.2025.09.023_bib63","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","article-title":"A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis","volume":"2","author":"Vincenti","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.09.023_bib64","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1681\/ASN.2015111230","article-title":"Anti-TGF-beta1 antibody therapy in patients with diabetic nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib65","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nm.2685","article-title":"A systems approach identifies HIPK2 as a key regulator of kidney fibrosis","volume":"18","author":"Jin","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2025.09.023_bib66","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms19061712","article-title":"The impact of the nitric oxide (NO)\/soluble guanylyl cyclase (sGC) signaling cascade on kidney health and disease: a preclinical perspective","volume":"19","author":"Krishnan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2025.09.023_bib67","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.kint.2019.02.016","article-title":"Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis","volume":"96","author":"Schley","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.09.023_bib68","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41581-020-0298-1","article-title":"Unravelling the complex genetics of common kidney diseases: from variants to mechanisms","volume":"16","author":"Sullivan","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2025.09.023_bib69","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/s41467-019-10378-8","article-title":"Kidney cytosine methylation changes improve renal function decline estimation in patients with diabetic kidney disease","volume":"10","author":"Gluck","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib70","doi-asserted-by":"crossref","first-page":"29013","DOI":"10.1073\/pnas.2005905117","article-title":"Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease","volume":"117","author":"Sheng","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.09.023_bib71","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.1038\/s41467-022-34963-6","article-title":"Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease","volume":"13","author":"Smyth","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160959","article-title":"Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes","volume":"133","author":"Khurana","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.09.023_bib73","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41588-022-01097-w","article-title":"Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease","volume":"54","author":"Liu","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2025.09.023_bib74","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1038\/s41467-022-32972-z","article-title":"Multimodal single cell sequencing implicates chromatin accessibility and genetic background in diabetic kidney disease progression","volume":"13","author":"Wilson","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib75","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41467-024-45295-y","article-title":"Unraveling the epigenetic code: human kidney DNA methylation and chromatin dynamics in renal disease development","volume":"15","author":"Yan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2025.09.023_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj3385","article-title":"Integrated analysis of blood DNA methylation, genetic variants, circulating proteins, microRNAs, and kidney failure in type 1 diabetes","volume":"16","author":"Chen","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825008385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:33:03Z","timestamp":1778941983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825008385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0085253825008385"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New potential therapeutic targets of metabolic disorder\u2013associated kidney disease and diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}